Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

218.98 +0.65 (+0.30%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
3 Blue-Chip Stocks Set to Make a Comeback in 2024
These are the blue-chip stocks to buy as they represent quality companies with a steady growth outlook and promising cash flow growth. 
Via InvestorPlace
$100 Invested In Seagen 20 Years Ago Would Be Worth This Much Today
Via Benzinga
TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
From Seagen Inc.
Via Business Wire
ImmunoGen Stock Nearly Doubled On Thursday: What Happened?
Shares of ImmunoGen Inc. close to doubled this morning after AbbVie Inc. said it will buy the cancer therapies company for $10.1 billion. 
Via Talk Markets
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
From Seagen Inc.
Via Business Wire
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,600 Today
Via Benzinga
Billionaire Favorites: 3 Ultra-High Yield Stocks the Elite Love
Buying stocks simple for their high dividend yields is risky but these are three stocks the elite love regardless. 
Via InvestorPlace
The 7 Most Undervalued Sleeper Stocks to Buy Now: November 2023
Here are just a few of the most undervalued sleeper stocks investors may want to consider heading into the new year. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
BioNTech Stock Surges On Surprise Profit, Strong Sales. But Report Has Downside.
The company was expected to report a third-quarter loss and plummeting sales. 
Via Investor's Business Daily
This Is The 'Only Solar Stock' Jim Cramer Is Recommending 'Because It's A Pure Play'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said DocuSign, Inc. 
Via Benzinga
Here's How Much You Would Have Made Owning Seagen Stock In The Last 15 Years
Via Benzinga
This High-Yield Dividend Stock Is a Proven Wealth Creator
This heavily sold-off pharma stock is a bargain. 
Via The Motley Fool
CPRI, SGEN, VMW: Why These 3 Stocks Are on the Tip of Bill Gross’ Tongue
Bill Gross, the Bond King, is wading into the world of equity arbitrage with these three stocks - but are they worth the risk for investors? 
Via InvestorPlace
Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Seagen Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate
From Seagen Inc.
Via Business Wire
Looking At Seagen's Recent Unusual Options Activity
Via Benzinga
Earnings Outlook For Seagen
Via Benzinga
Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress
From Seagen Inc.
Via Business Wire
The 7 Most Undervalued Long-Term Stocks to Buy: October 2023
Equities remain under pressure, but if you’re looking to be a contrarian investor, it’s a good time to look for undervalued long-term stocks. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Seagen Inc. (NASDAQ: SGEN) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
Seagen Inc. (NASDAQ: SGEN) Climbs to New 52-Week High
Via Investor Brand Network
Earnings Scheduled For November 1, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion. 
Via Benzinga
(SGEN) - Analyzing Seagen's Short Interest
Via Benzinga
How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks
The companies studied a combination of Keytruda and Padcev in bladder cancer patients. 
Via Investor's Business Daily
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
From Seagen Inc.
Via Business Wire
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
From Seagen Inc.
Via Business Wire
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
The venerable pharmaceutical companies' shares have slumped this year. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.